相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
S. L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy
James N. Kochenderfer et al.
MOLECULAR THERAPY (2017)
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
S. S. Neelapu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL
Xiuli Wang et al.
BLOOD (2016)
Generation of clinical-grade CD19-specific CAR-modified CD8+ memory stem cells for the treatment of human B-cell malignancies
Marianna Sabatino et al.
BLOOD (2016)
Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells (vol 44, pg 380, 2016)
Omkar U. Kawalekar et al.
IMMUNITY (2016)
Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia
Paulina J. Paszkiewicz et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Extending the half-life of a fab fragment through generation of a humanized anti-human serum albumin Fv domain: An investigation into the correlation between affinity and serum half-life
Ralph Adams et al.
MABS (2016)
Versatile strategy for controlling the specificity and activity of engineered T cells
Jennifer S. Y. Ma et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies
David T. Rodgers et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells
Zeguo Zhao et al.
CANCER CELL (2015)
Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor
James N. Kochenderfer et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Identification and selective expansion of functionally superior T cells expressing chimeric antigen receptors
ZeNan L. Chang et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2015)
Chimeric Antigen Receptors With Mutated IgG4 Fc Spacer Avoid Fc Receptor Binding and Improve T Cell Persistence and Antitumor Efficacy
Mahesh Jonnalagadda et al.
MOLECULAR THERAPY (2015)
4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors
Adrienne H. Long et al.
NATURE MEDICINE (2015)
The pharmacology of second-generation chimeric antigen receptors
Sjoukje J. C. van der Stegen et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma
Alfred L. Garfall et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia
David L. Porter et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
The Nonsignaling Extracellular Spacer Domain of Chimeric Antigen Receptors Is Decisive for In Vivo Antitumor Activity
Michael Hudecek et al.
CANCER IMMUNOLOGY RESEARCH (2015)
EGFRvIII mCAR-Modified T-Cell Therapy Cures Mice with Established Intracerebral Glioma and Generates Host Immunity against Tumor-Antigen Loss
John H. Sampson et al.
CLINICAL CANCER RESEARCH (2014)
Design and development of therapies using chimeric antigen receptor-expressing T cells
Gianpietro Dotti et al.
IMMUNOLOGICAL REVIEWS (2014)
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Shannon L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Tolerance and exhaustion: defining mechanisms of T cell dysfunction
Andrea Schietinger et al.
TRENDS IN IMMUNOLOGY (2014)
Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia
Waleed Haso et al.
BLOOD (2013)
Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia
Stephan A. Grupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
CD19 CAR-Targeted T Cells Induce Long-Term Remission and B Cell Aplasia in an Immunocompetent Mouse Model of B Cell Acute Lymphoblastic Leukemia
Marco L. Davila et al.
PLOS ONE (2013)
Sorting Through Subsets: Which T-Cell Populations Mediate Highly Effective Adoptive Immunotherapy?
Christopher A. Klebanoff et al.
JOURNAL OF IMMUNOTHERAPY (2012)
Genetic Engineering of Murine CD8+ and CD4+ T Cells for Preclinical Adoptive Immunotherapy Studies
Sid P. Kerkar et al.
JOURNAL OF IMMUNOTHERAPY (2011)
T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia
Michael Kalos et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells
James N. Kochenderfer et al.
BLOOD (2010)
4-1BB and CD28 Signaling Plays a Synergistic Role in Redirecting Umbilical Cord Blood T Cells Against B-Cell Malignancies
Syam Tammana et al.
HUMAN GENE THERAPY (2010)
Natural Expression of the CD19 Antigen Impacts the Long-Term Engraftment but Not Antitumor Activity of CD19-Specific Engineered T Cells
Eleanor J. Cheadle et al.
JOURNAL OF IMMUNOLOGY (2010)
Chimeric Antigen Receptors Combining 4-1BB and CD28 Signaling Domains Augment PI3kinase/AKT/Bcl-XL Activation and CD8+ T Cell-mediated Tumor Eradication
Xiao-Song Zhong et al.
MOLECULAR THERAPY (2010)
Construction and Preclinical Evaluation of an Anti-CD19 Chimeric Antigen Receptor
James N. Kochenderfer et al.
JOURNAL OF IMMUNOTHERAPY (2009)
Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In Vivo
Michael C. Milone et al.
MOLECULAR THERAPY (2009)
The combination of cyclophosphamide and human T cells genetically engineered to target CD19 can eradicate established B-cell lymphoma
Eleanor J. Cheadle et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
4-1BB is superior to CD28 costimulation for generating CD8+ cytotoxic lymphocytes for adoptive immunotherapy
Hua Zhang et al.
JOURNAL OF IMMUNOLOGY (2007)
Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration
Laura Bracci et al.
CLINICAL CANCER RESEARCH (2007)
CD45RA on human CD8 T cells is sensitive to the time elapsed since the last antigenic stimulation
Javier Carrasco et al.
BLOOD (2006)
CD8(+) T-cell memory in tumor immunology and immunotherapy
Christopher A. Klebanoff et al.
IMMUNOLOGICAL REVIEWS (2006)
An inducible caspase 9 safety switch for T-cell therapy
KC Straathof et al.
BLOOD (2005)
Fab antibody fragments - Some applications in clinical toxicology
RJ Flanagan et al.
DRUG SAFETY (2004)
CD28-mediated co-stimulation: A quantitative support for TCR signalling
O Acuto et al.
NATURE REVIEWS IMMUNOLOGY (2003)
Lineage relationship and protective immunity of memory CD8 T cell subsets
EJ Wherry et al.
NATURE IMMUNOLOGY (2003)
Differential regulation of antiviral T-cell immunity results in stable CD8+ but declining CD4+ T-cell memory
D Homann et al.
NATURE MEDICINE (2001)